Status:
TERMINATED
Effect of Furosemide on Obesity-induced Glomerular Hyperfiltration
Lead Sponsor:
Rabin Medical Center
Conditions:
Obesity-induced Hyperfiltration
Eligibility:
MALE
18-55 years
Phase:
NA
Brief Summary
Background: Obesity is associated with a high prevalence of chronic kidney disease. The glomerular hyperfiltration associated with obesity may play a role in the pathogenesis of obesity associated chr...
Detailed Description
Almost half of the causes of death in the industrial world are due to cardio-vascular disease. Two of the main risk factors for CV disease have become much more prevalent during the last decades, reac...
Eligibility Criteria
Inclusion
- 10 obese men (BMI\>30), aged 18 to 55, with glomerular hyperfiltration (creatinine clearance\>130 ml/min) will be included in the study.
Exclusion
- Any of the following conditions:
- Heart failure
- Known allergy to furosemide, inulin or amino-hippurate
- Pharmacologic treatment for hypertension, cardiac disease, diabetes mellitus
- Treatment with corticosteroids or NSAID
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00962286
Start Date
September 1 2009
End Date
July 1 2010
Last Update
August 4 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center
Petah Tikva, Israel